Could Trump's 'Go Wild On Health' Invite To RFK Jr. Drive Changes For Cannabis And Psychedelics?

President-elect Donald Trump has publicly suggested that Robert F. Kennedy Jr. could play a key role in his administration to drive forward his “Make America Healthy Again” agenda. While the exact nature of Kennedy's appointment remains uncertain, Trump's statements have stirred discussions about potential shifts in U.S. drug policy, particularly regarding cannabis and psychedelics, which Kennedy has been vocal about supporting.

What To Know: Trump's Open Invitation For Kennedy To ‘Go Wild On Health’

Trump recently indicated that Kennedy would have significant influence, saying he would let him "go wild on health" and allow him to “do pretty much what he wants.” However, details remain unconfirmed, and no specific role has been formally announced.

Kennedy's outspoken stances on cannabis and psychedelics suggest that, if given the authority, he could champion regulatory changes in these areas. However, his potential appointment has also prompted concerns, especially from public health advocates, about his past assertions on vaccines. Kennedy has previously promoted the debunked theory that vaccines are linked to autism, a claim thoroughly discredited by scientific studies, according to The New York Times. The U.S. has seen an increase in measles outbreaks recently, with the CDC reporting thirteen outbreaks in 2024 compared to four the previous year, a trend some link to declining vaccination rates.

Potential Influence On Cannabis Policy

Kennedy has expressed support for federal decriminalization of cannabis. In previous interviews, he proposed a model allowing states to regulate cannabis as they see fit while generating federal revenue from cannabis taxes to fund rehabilitation centers. These centers, which Kennedy envisions in rural areas, would focus on holistic recovery practices, including activities like gardening and forestry. His approach to cannabis reform centers on reducing federal barriers while using tax revenues for public health initiatives.

Another priority for Kennedy, should he influence federal cannabis policy, is securing safe banking access for the industry. Many cannabis businesses operate on a cash-only basis due to federal restrictions, increasing security risks and limiting financial service access. Kennedy has advocated for reforms that would integrate cannabis businesses into the formal banking sector, aiming to improve safety and efficiency within the industry.

Psychedelics Policy: Personal Experience Shapes Kennedy's Stance

Kennedy's views on psychedelics have been shaped by personal experiences and the growing acceptance of psychedelics as potential treatments for mental health conditions. In a podcast interview with the Genius Network, he recounted his son's transformative experience with ayahuasca, a psychoactive substance, which Kennedy said helped him process grief. This experience, along with testimonies from veterans and athletes, has led Kennedy to support the decriminalization of psychedelics, particularly in therapeutic settings.

“My inclination would be to make them available, at least in therapeutic settings and maybe more generally, but in ways that would discourage corporate control and exploitation,” Kennedy shared, signaling a cautious approach to psychedelics legalization.

Looking Ahead: Will Kennedy Reshape Cannabis and Psychedelics Policy?

While Trump has promised Kennedy significant influence, the exact role and scope of his authority remain unclear. As details emerge, many will be watching to see if Kennedy can advance his pro-cannabis and psychedelics agenda within the new administration. His focus on individual liberties and health agency reform suggests he may push for more liberal policies regarding cannabis and psychedelics, though it's unclear how these initiatives might align with broader federal policy.

Kennedy has hinted that he could serve as a "White House health czar," giving him the latitude to guide health policy without directly leading any specific agency. However, the specifics remain fluid, and public health experts and investors alike will continue monitoring developments closely.

Photo: Shutterstock